IL27 and prostate carcinoma: For the second model examined, when we assessed the expression of IL-27α on the surface of prostate-cancer cells (PC3 and C4-2B) only negligible levels were detected, with 3.77% of PC3 and 0.26% of C4-2B cells displaying the receptor relative to their unstained controls (Figure 4I–L).